"The voice for cancer physicians and their patients in Massachusetts."

FDA APPROVALS

Complete List of FDA Oncology Approval Notifications

To see a complete list of FDA Oncology (Cancer) / Hematologic Malignancies Approval Notifications, visit the FDA's website.

FDA WEBSITE


Upcoming events

  • No upcoming events

MSCO CORPORATE MEMBER APPROVALS

  • 23 Sep 2022 8:30 AM | Katy Monaco (Administrator)

    The Food and Drug Administration granted regular approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.  Today, FDA also approved the Oncomine Dx Target (ODxT) Test (Thermo Fisher Scientific) as a companion diagnostic for selpercatinib.  Read more


  • 06 Sep 2022 8:51 AM | Katy Monaco (Administrator)

    The Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca UK Limited) in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer (BTC). More information

    The attached document provides a summary of key results from the TOPAZ-1 trial, along with other important information about the use of IMFINZI in patients with advanced BTCs.

  • 29 Aug 2022 8:53 AM | Katy Monaco (Administrator)

    The Food and Drug Administration approved pemigatinib (Pemazyre, Incyte Corporation) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement. More information

  • 26 Aug 2022 7:08 AM | Katy Monaco (Administrator)

    The Food and Drug Administration approved ibrutinib (Imbruvica, Pharmacyclics LLC) for pediatric patients ≥ 1 year of age with chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy. Formulations include capsules, tablets, and oral suspension.  For more information, read the FDA Announcement or Press Release.

  • 12 Aug 2022 10:19 AM | Katy Monaco (Administrator)

    Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. This is the first drug approved for HER2-mutant NSCLC. For more information about this approval, you can find Daiichi Sankyo’s press release here and AstraZeneca’s press release here. 

    See the FDA approved indication and Important Safety Information below. Please see accompanying full Prescribing Information, including Boxed WARNINGS, and Medication Guide.

  • 12 Aug 2022 10:18 AM | Katy Monaco (Administrator)

    Food and Drug Administration granted regular approval to capmatinib (Tabrecta, Novartis Pharmaceuticals Corp.) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.  Read More

  • 05 Aug 2022 5:00 PM | Katy Monaco (Administrator)

    The Food and Drug Administration approved darolutamide (Nubeqa, Bayer HealthCare Pharmaceuticals Inc.) tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC). Read More.

  • 05 Aug 2022 3:00 PM | Katy Monaco (Administrator)
    The Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH‑) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy. Read More.
  • 18 Jul 2022 7:49 AM | Katy Monaco (Administrator)

    The FDA approves crizotinib (Xalkori, Pfizer Inc.) for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT).  Read More

  • 27 Jun 2022 2:22 PM | Katy Monaco (Administrator)

    Bristol Myers Squibb announced that the FDA has approved Breyanzi® (lisocabtagene maraleucel) for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:  • Refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or  • Refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplant (HSCT) due to comorbidities or age.  More Information


Massachusetts Society of Clinical Oncologists ©2023

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  email: msco@mms.org


Powered by Wild Apricot Membership Software